Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Aug;138(2):589-592.e2.
doi: 10.1016/j.jaci.2015.12.1329. Epub 2016 Mar 11.

Vitamin D3 therapy in patients with asthma complicated by sinonasal disease: Secondary analysis of the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma trial

Junfang Jiao  1 , Tonya S King  2 , Matthew McKenzie  3 , Leonard B Bacharier  4 , Anne E Dixon  5 , Christopher D Codispoti  6 , Ryan M Dunn  7 , Nicole L Grossman  8 , Njira L Lugogo  9 , Sima K Ramratnam  10 , Russell S Traister  11 , Michael E Wechsler  12 , Mario Castro  13 ; National Heart, Lung, and Blood Institute's AsthmaNet
Affiliations
Randomized Controlled Trial

Vitamin D3 therapy in patients with asthma complicated by sinonasal disease: Secondary analysis of the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma trial

Junfang Jiao et al. J Allergy Clin Immunol. 2016 Aug.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Responses to vitamin D3 supplementation in asthmatics with and without sinonasal disease. A, Baseline 25-hydroxyvitamin D levels were compared to the levels 12 weeks after randomization to placebo or vitamin D3 in those with sinonasal disease and without the disease. B, Similar comparison between black and non-black subjects. Data are represented as mean ± SD. C, Changes in the percentage of sinonasal disease in placebo and vitamin D3 groups. D, Changes in SNQ scores in response to vitamin D3 and placebo. E, Response to vitamin D3 and placebo in black and non-black subjects with sinonasal disease.
Fig 1
Fig 1
Responses to vitamin D3 supplementation in asthmatics with and without sinonasal disease. A, Baseline 25-hydroxyvitamin D levels were compared to the levels 12 weeks after randomization to placebo or vitamin D3 in those with sinonasal disease and without the disease. B, Similar comparison between black and non-black subjects. Data are represented as mean ± SD. C, Changes in the percentage of sinonasal disease in placebo and vitamin D3 groups. D, Changes in SNQ scores in response to vitamin D3 and placebo. E, Response to vitamin D3 and placebo in black and non-black subjects with sinonasal disease.
Fig 1
Fig 1
Responses to vitamin D3 supplementation in asthmatics with and without sinonasal disease. A, Baseline 25-hydroxyvitamin D levels were compared to the levels 12 weeks after randomization to placebo or vitamin D3 in those with sinonasal disease and without the disease. B, Similar comparison between black and non-black subjects. Data are represented as mean ± SD. C, Changes in the percentage of sinonasal disease in placebo and vitamin D3 groups. D, Changes in SNQ scores in response to vitamin D3 and placebo. E, Response to vitamin D3 and placebo in black and non-black subjects with sinonasal disease.
Fig 1
Fig 1
Responses to vitamin D3 supplementation in asthmatics with and without sinonasal disease. A, Baseline 25-hydroxyvitamin D levels were compared to the levels 12 weeks after randomization to placebo or vitamin D3 in those with sinonasal disease and without the disease. B, Similar comparison between black and non-black subjects. Data are represented as mean ± SD. C, Changes in the percentage of sinonasal disease in placebo and vitamin D3 groups. D, Changes in SNQ scores in response to vitamin D3 and placebo. E, Response to vitamin D3 and placebo in black and non-black subjects with sinonasal disease.
Fig 1
Fig 1
Responses to vitamin D3 supplementation in asthmatics with and without sinonasal disease. A, Baseline 25-hydroxyvitamin D levels were compared to the levels 12 weeks after randomization to placebo or vitamin D3 in those with sinonasal disease and without the disease. B, Similar comparison between black and non-black subjects. Data are represented as mean ± SD. C, Changes in the percentage of sinonasal disease in placebo and vitamin D3 groups. D, Changes in SNQ scores in response to vitamin D3 and placebo. E, Response to vitamin D3 and placebo in black and non-black subjects with sinonasal disease.
See this image and copyright information in PMC

References

    1. Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA. 2014;311:2083–2091. - PMC - PubMed
    1. Mulligan JK, Bleier BS, O'Connell B, Mulligan RM, Wagner C, Schlosser RJ. Vitamin D3 correlates inversely with systemic dendritic cell numbers and bone erosion in chronic rhinosinusitis with nasal polyps and allergic fungal rhinosinusitis. Clin Exp Immunol. 2011;164:312–320. - PMC - PubMed
    1. Mulligan JK, Nagel W, O'Connell BP, Wentzel J, Atkinson C, Schlosser RJ. Cigarette smoke exposure is associated with vitamin D3 deficiencies in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2014;134:342–349. - PubMed
    1. Dixon AE, Sugar EA, Zinreich SJ, Slavin RG, Corren J, Naclerio RM, et al. Criteria to screen for chronic sinonasal disease. Chest. 2009;136:1324–1332. - PMC - PubMed
    1. Pinto JM, Schneider J, Perez R, DeTineo M, Baroody FM, Naclerio RM. Serum 25-hydroxyvitamin D levels are lower in urban African American subjects with chronic rhinosinusitis. J Allergy Clin Immunol. 2008;122:415–417. - PubMed

Associated data